Global Diagnostics Reach IMMY already serves over 100 countries with rapid detection of diverse fungal pathogens, signaling strong international demand and partnership potential with hospitals, regional distributors, and public health programs.

Antifungal Stewardship The company focus on antifungal stewardship positions its tests as a value add for hospitals seeking to optimize antifungal use and reduce costs, creating opportunities for bundled solutions, implementation support, and payer engagement.

Mid Market Focus With a staff size of 51 to 200 and revenue in the mid tens of millions, IMMY sits in a sweet spot for regional health systems and mid sized labs. Sales plays can target multi site hospital networks, reference labs, and regional distributors to scale adoption of fungal diagnostics.

Portfolio Growth IMMY's emphasis on early detection across fungal pathogens suggests room to expand into additional panels, point of care formats, or multiplex assays and hybrid diagnostics to broaden use cases across inpatient and outpatient settings.

Digital and Partnerships Leveraging its tech stack and global reach, the company can accelerate lead generation and ordering through digital channels, pursue partnerships with distributors and biotech firms, and enhance field sales with data driven insights and remote support.